Anti-NMDA Receptor Encephalitis

This is a rare brain disorder. It happens when the body's immune system mistakenly attacks the NMDA receptors in the brain. This attack causes symptoms like confusion, seizures, muscle spasms, and loss of consciousness. It often starts with flu-like symptoms. Most cases get better on their own, but some need special treatments to help the immune system calm down.

Condition

What people with Anti-NMDA Receptor Encephalitis report

Every report comes from a Lived member, sent anonymously.

Have you tried IVIG for Anti-NMDA Receptor Encephalitis?

NameHow it went

About Anti-NMDA Receptor Encephalitis

What It Is

Anti-NMDA receptor encephalitis is an autoimmune disease in which the immune system makes antibodies against the N-methyl-D-aspartate (NMDA) receptor, a protein that nerve cells use to signal to one another and that matters for memory, thinking and behavior. The antibodies disrupt that signaling and cause encephalitis, meaning inflammation of the brain. Symptoms develop quickly, and within about a month most people have several different kinds of symptoms. In teenagers and adults, the illness usually begins with changes that look psychiatric: irritability, insomnia, agitation, delusions, hallucinations, aggression or catatonia (being stuck, mute or unresponsive). Speech problems, memory loss, seizures, involuntary movements of the face or limbs, swings in heart rate and blood pressure, and reduced consciousness often follow. Young children more often start with seizures or abnormal movements. Because the early picture can resemble a first episode of psychosis, the condition may at first be mistaken for a psychiatric illness. The disease is rare. It mostly affects young people (about a third of patients are under 18), and about four in five are female. Most people become seriously ill and need hospital care, often in intensive care, but most improve with treatment.

Causes & Risk Factors

The illness begins when the immune system starts producing antibodies against the NMDA receptor. In some people an identifiable trigger sets this off; in others no trigger is found. The best-known trigger is a tumor, most often an ovarian teratoma, a growth of the ovary that is usually not cancerous. In the largest study, about 4 in 10 people had a tumor. Tumors are found most often in women between their teens and mid-40s. They are rare in children under 12, and when adults over 45 have a tumor, it is more often a cancer than a teratoma. Men are affected less often and rarely have a tumor. A brain infection with herpes simplex virus (herpes simplex encephalitis) can also trigger it. In a prospective study, about a quarter of people treated for herpes simplex encephalitis went on to develop autoimmune encephalitis, usually within two months, and NMDA receptor antibodies were the most common type. It appears as new or returning neurological or behavioral symptoms after the infection seemed to be improving.

How It's Diagnosed

Diagnosis starts with recognizing the pattern: new psychiatric or behavioral symptoms that are joined, over days or weeks, by problems such as seizures, speech changes, abnormal movements or reduced alertness. Once that pattern is clear and other causes, especially infection, have been reasonably ruled out, doctors can begin treatment and the tumor search without waiting for every result. The confirming test looks for antibodies against the NMDA receptor. Testing cerebrospinal fluid, the fluid around the brain and spinal cord collected by a lumbar puncture (spinal tap), is more reliable than a blood test: in a large study, the spinal fluid test detected the antibodies in all paired samples, while blood tests missed about 15% of cases. The spinal fluid often also shows signs of inflammation, and it is tested for viruses such as herpes. An EEG, which records the brain's electrical activity, was abnormal in about 9 in 10 people in that study, while a brain MRI (magnetic resonance imaging) scan was abnormal in only about a third. A normal MRI therefore does not rule the condition out. Because of the tumor link, young and middle-aged adults with the typical picture are checked for a teratoma, usually with a pelvic ultrasound in women (MRI if the ultrasound is unclear) or a testicular ultrasound in men.

Treatment Options

Treatment aims to stop the immune attack, remove a tumor if one is found, and support the brain and body while recovery happens. Starting immunotherapy early is linked to better outcomes. First-line immunotherapy usually means high-dose corticosteroids (steroid medicines that calm inflammation), intravenous immunoglobulin (IVIG, antibodies from donated blood given by infusion to dampen the immune response), plasma exchange (a procedure that filters antibodies out of the blood), or a combination of these. In the largest study, about half of people improved within four weeks of first-line treatment or tumor removal. When there is no clear improvement, doctors move to second-line drugs, most often rituximab, an infused antibody medicine that removes the B cells that make antibodies, or cyclophosphamide, a stronger immune-suppressing drug. In that study, people who did not respond to first-line treatment did better when they received second-line treatment. Second-line treatment also lowered the chance of relapse in people without a tumor. Other drugs are being studied for people who still do not respond. When a teratoma is found, removing it is a central part of treatment. Hospital care also controls seizures and agitation, supports breathing when needed, and manages swings in heart rate and blood pressure. Rehabilitation for movement, speech, thinking and daily skills often continues after discharge.

What to Expect

The acute illness is usually severe and often means a long hospital stay. Recovery is slow. In the largest study, people who reached a good outcome got there after a median of about six months, and some kept improving for up to 18 months. About 8 in 10 people followed for two years had a good outcome, meaning they could manage their own daily life. Severe cases can be fatal: in that cohort, studied between 2007 and 2012, about 1 in 10 people died within two years. A good outcome on standard disability scores does not always mean a full return to how things were before. In a study of adults assessed more than six months after onset, moderate to severe problems with thinking and memory, depression and anxiety were common. Problems with attention, planning, mood, energy and sleep can affect school, work and relationships, and returning to them is often gradual. Relapses occurred in about 1 in 8 people within two years, more often in those without a tumor. Most relapses were milder than the first episode, and people treated with immunotherapy during the first episode relapsed less often. Follow-up with a neurologist continues after discharge to watch for relapse and track recovery.

When to Seek Help

Seek same-day medical assessment when new psychiatric symptoms appear suddenly together with confusion, memory loss, speech changes, unusual movements or severe sleep disruption. It is reasonable to ask whether autoimmune encephalitis has been considered. Call 911 for a seizure, if the person becomes hard to wake or unresponsive, or if breathing becomes slow or shallow. After recovery, or in the weeks after treatment for herpes simplex encephalitis, contact the neurology team promptly if changes in behavior, memory, movement or sleep return or appear, since a relapse or new autoimmune encephalitis responds best to early treatment.

Questions to Ask Your Doctor

  1. 1.Has autoimmune encephalitis been tested for, and was the antibody test done on spinal fluid as well as blood?
  2. 2.Was a tumor found, and is any further screening needed if none was found?
  3. 3.How will we judge whether first-line treatment is working, and when would you move to second-line treatment?
  4. 4.What will recovery involve, including rehabilitation, testing of memory and thinking, and returning to school or work?
  5. 5.What are the early signs of a relapse, and whom should we contact if they appear?

Last reviewed • Oct 2026

Educational content, not medical advice.